Expression of MCM5 in Urine in Patients With Urothelial Cancers

计划入组 180 人 · 首次发布于 2019 年 1 月 8 日

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

首次发布于 2023 年 6 月 8 日

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

计划入组 162 人 · 首次发布于 2026 年 4 月 22 日

Werner inhibitor (MSI-high cancers/sensitive cancers)

Kras Inhibitor (cancers)

C-4

ASSO DE RECHERCHE CANCERS GYNECOLOGIQUES

France

Revolution Medicines, Inc.

United States

PDS Biotechnology

United States

Ferring Advances Nadofaragene Firadenovec Clinical Program in Urothelial Cancers

TYRA-300: Novel FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer and Achondroplasia

Role of Immunotherapy in Bladder Cancer